KOD - Is This Mid-Cap Biotech Stock a Buy Now?
Kodiak Sciences (NASDAQ: KOD) is a mid-cap biotech business building a drug portfolio focused on retina therapeutics. The Palo Alto, California based company has an approximate market cap of $4.5 billion. Kodiak launched its IPO in 2018, and it has been heads down pushing its pipeline through clinical trials since.
One of the company's focus areas is the global "wet AMD" market, where it faces direct competition from Regeneron 's (NASDAQ: REGN) Eylea (aflibercept) injection. The global wet AMD market is estimated to have a total addressable market of $10.4 billion by 2024. Kodiak's KSI-301 has proven to help with wet AMD, but also with diabetic macular edema and retina vein occlusion. Because of this, the chances of drug approval seem very high. In fact, the company's website shows four primary areas in phase 3 for KSI-301: wet age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and diabetic retinopathy.
Kodiak reported a $50.4 million net loss in its most recent quarter, but it does have a healthy balance sheet. As of March 31, 2021, Kodiak Sciences held $930 million in cash, cash equivalents, and market securities. This should be plenty of cash to get the company through its primary clinical studies.
For further details see:
Is This Mid-Cap Biotech Stock a Buy Now?